The video highlights Immunis’ commitment to transparency. Immunis provides an in-depth look at the company’s intellectual foundation and cooperative efforts in bringing its investigational secretome to clinical trials. Viewers can get a glimpse of the company’s state-of-the-art facilities, meet some brilliant team members, and hear about the carefully regulated process involved in creating IMMUNA.
As always, Immunis is devoted to ensuring safety and efficacy, as well as advancing the science and understanding of age-related disease and patient care. If you would like to hear more about Immunis’ journey or become more familiarized with the latest on aging and longevity research, please visit our website for lots of great content!
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.